Last Monday, the U.S. Department of Health and Human Services (HHS) finalized 10,000 layoffs across federal health agencies, including the National Institutes of Health (NIH), U.S. Food and Drug ...

Dr. Peter Marks, the former director of the FDA’s Center for Biologics Evaluation and Research, urged public health leaders ...

The Good Food Collective, a new coalition of 25-plus food brands, organizations, and nutrition experts, has teamed up to ...

A recipient of the 2025 Elite Trial Lawyers Lifetime Achievement Award, Morgan & Morgan's John Yanchunis spoke with the National Law Journal about his storied career, from bringing one of the nation’s ...

An estimated 53 drugs would not enter the market in the next 30 years if the NIH is hit with a permanent 10% budget cut and the FDA experiences a nine-month drug review delay due to staffing cuts, the ...

According to the company's global financial results for the first quarter, released in May, declines of 19 percent in the ...

Other agencies are moving forward with RIFs and terminations, but official tells federal court some plans have changed.

The investigative unit, which looks into potential safety issues with drugs, vaccines, medical devices, and other products, has had a retention problem for years. Inspectors leave so often that, even ...

Loss of support staff has slowed critical investigations of drug manufacturers. Little relief has materialized.

Federal agency leaders still face obstacles to implementing widespread layoffs, and some are even reversing course after the ...

The number of employees laid off and companies letting people go increased year over year during the first half of 2025.

Beyond staff cuts, the departures of investigators in recent months have left less experienced people tasked with rooting out dangerous manufacturing practices.